A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 [lapaquistat] and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Lapaquistat; Simvastatin
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 14 Jan 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from discontinued to completed, as reported by Clinicaltrials.gov.